CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 159 enrolled
Drug / intervention
Axicabtagene ciloleucel +2 morebiological
Likely dose
Axicabtagene ciloleucel administered intravenously (specific dose not stated in protocol)AI-extracted
Key inclusion· 4
  • ✓Follicular lymphoma or marginal zone lymphoma with disease progression after at least 2 prior lines of combination chemoimmunotherapy
  • ✓Measurable disease present
  • ✓No known CNS involvement by lymphoma
  • ✓ECOG performance status 0-1 with adequate renal, hepatic, pulmonary, and cardiac function
Key exclusion· 5
  • ✕Transformed follicular or marginal zone lymphoma
  • ✕Small lymphocytic lymphoma
  • ✕Histological Grade 3b follicular lymphoma
  • ✕Autologous transplant within 6 weeks of leukapheresis or any prior allogeneic transplant

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03105336
NCT03105336Phase 2Completed
CompareCT.gov

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Kite, A Gilead Company·interventional·Posted Apr 7, 2017·Updated Dec 23, 2025

In Brief

A Phase 2 clinical trial evaluating Axicabtagene ciloleucel, Cyclophosphamide, and 1 other intervention for Follicular Lymphoma and 2 related conditions. Completed, enrolled 159 participants across 19 sites in 2 countries.

Detailed Summary

The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
CountriesFrance, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 7, 2017
Enrollment StartJun 6, 2017
Primary CompletionDec 20, 2024
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 9.2 years ago

Interventions

Axicabtagene ciloleucelbiological

Administered intravenously

Cyclophosphamidedrug

Administered intravenously

Fludarabinedrug

Administered intravenously